Search
Cyclophosphamide Treatment Options in Boston, MA
A collection of 351 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the Boston, MA. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
337 - 348 of 351
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Evaluating an Investigational Treatment for Hidradenitis Suppurativa
Recruiting
The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.
Conditions:
All Conditions
Hidradenitis suppurativa (Skin disorder)
Dermatology
SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant
Completed
RATIONALE: Reducing the amount of drugs used to prevent transplant rejection may help a person's body kill tumor cells. Giving biological therapy, such as interferon alfa, which may interfere with the growth of cancer cells, or combination chemotherapy, which uses different ways to stop tumor cells from dividing so they stop growing or die, may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of reducing immunosuppression, and giving interferon alfa and combination chem... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
01/22/2013
Locations: Boston Medical Center, Boston, Massachusetts +1 locations
Conditions: Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known if combination chemotherapy is more effective with or without peripheral stem cell transplantation in treating Hodgkin's Disease.
PURPOSE: Randomized phase III trial to compare the effectiveness of combi... Read More
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
01/22/2013
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Lymphoma
SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Antiviral therapy may be effective treatment for AIDS-related lymphoma.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, radiation therapy, and antiviral therapy in treating patients who have AIDS-related lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2013
Locations: Boston Medical Center, Boston, Massachusetts +1 locations
Conditions: Lymphoma
Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of doxorubicin, cyclophosphamide, and docetaxel in treating women with stage IIIB or stage IV breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/10/2012
Locations: New England Medical Center Hospital, Boston, Massachusetts +4 locations
Conditions: Breast Cancer
Ph II CHOP+Velcade in Mediastinal LBCL
Terminated
The main purpose of this study is to begin to collect information and try to learn whether or not VELCADE, when added to standard chemotherapy with CHOP/Rituxan, works in treating patients mediastinal large B-cell lymphoma. Recent research has shown that this type of lymphoma shares features with Hodgkin's lymphoma, including the importance of a particular pathway in the tumor cells called the NF-kB pathway. VELCADE works in part by blocking this pathway.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/30/2012
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Non-Hodgkin's Lymphoma
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
Completed
The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
11/02/2012
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Leukemia, Myelocytic, Acute
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
Completed
To estimate the response rate, overall and disease-free survival, toxicities, factors associated with outcome, and effect on quality of life in patients with AIDS-related primary CNS lymphoma treated with CHOD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) plus filgrastim (granulocyte-colony stimulating factor; G-CSF) and external beam irradiation. To determine other clinical markers present in this patient population.
Combined modality therapy may prove of benefit for patients... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
10/31/2012
Locations: Beth Israel Deaconess - West Campus, Boston, Massachusetts +1 locations
Conditions: Lymphoma, Non-Hodgkin, HIV Infections
S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining cyclophosphamide, methotrexate, and fluorouracil in treating patients with Merkel cell cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2012
Locations: Boston Medical Center, Boston, Massachusetts +1 locations
Conditions: Neuroendocrine Carcinoma of the Skin
A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.
Completed
This 2 arm study assessed the efficacy of Mycophenolate Mofetil (MMF; CellCept) compared to cyclophosphamide in inducing a response in patients with lupus nephritis, and the long term efficacy of MMF compared to azathioprine in maintaining remission and renal function. Patients were randomized to receive either MMF (1.5 g twice daily \[bid\]) or cyclophosphamide (0.5-1.0 g/m\^2 in monthly pulses) in the induction phase. Those patients meeting criteria for response were re-randomized for entry in... Read More
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
10/31/2011
Locations: Not set, Boston, Massachusetts
Conditions: Lupus Nephritis
A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer
Completed
This study will use a combination of four oral drugs (thalidomide, cyclophosphamide, etoposide and celecoxib) to treat patients with relapsed or progressive cancer. These drugs are expected to target the blood vessels that supply the tumors with what they need to grow.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
07/06/2011
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Neoplasms
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
Completed
The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death after 3 years. The study will also evaluate the side effects of both treatment combinations.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/24/2011
Locations: Pfizer Investigational Site, Boston, Massachusetts
Conditions: Adenocarcinoma
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
Completed
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
PURPOSE: Phase II trial to study the effectiveness of allogeneic umbilical cord blood transplantation in treating patients who have leukemia, lymphoma, or nonmalignant hematologic disorders.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
03/03/2011
Locations: Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases
337 - 348 of 351